
Opinion|Videos|July 18, 2024
TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations
Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5




















